BioCryst Pharma (BCRX) Reports Q4 Loss Per Share of 6c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $10.07 +3.81%
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
JAGX, CLIR, ZTO, More
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
JAGX, CLIR, ZTO, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.06), $0.17 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $9 million versus the consensus estimate of $4.13 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- TJX stock drops as profit outlook falls short of analyst estimates
- Beam Global (BEEM) Tops Q2 EPS by 8c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
